source
- AstraZeneca says Wainua failure won’t alter M&A plans, stays on track for $80B 2030 goalAstraZeneca said during its Q2 earnings presentation that the late‑stage failure of the antisense therapy Wainua in ATTR‑cardiomyopathy does not derail its goal of reaching $80 billion in revenue b…
- Legend Biotech CEO Ying Huang resigns, interim leader Alan Bash appointedLegend Biotech announced that its chief executive, Ying Huang, Ph.D., stepped down on Friday, with no permanent successor named yet. The board named Alan Bash as interim CEO on July 23, according…